SAS and Carolina partner to accelerate antiviral drug development
Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI).
(UNC.edu)
Related: Campus Connections
Tar Heel hoists the Stanley Cup — twiceMallory Wilmoth knows how much the Stanley Cup weighs. It’s about 35 pounds and can be cumbersome to lift, especially while standing on ice in...
Wed Jul 8, 2026UNC student, Rhodes scholar brings hope back home to Jamaica
When Tiana Dinham flew home to Jamaica in November 2025, the University of North Carolina senior experienced the “lowest of lows and highest of highs.”...
Tue Jul 7, 2026
How Chapel Hill will use parking to keep a homegrown robotics company downtown
As an advanced robotics and precision software company working with health care, logistics, manufacturing and hospitality users, Blue Sky Robotics Inc. has high-growth opportunities, said...
Sun Jul 5, 2026
University Founder William R. Davie’s Halifax Home Restored
About 235 years ago, William Davie hitched his horse to a poplar tree, sat in the grass for a summer lunch and had such a...
Fri Jul 3, 2026
